OncoCyte Corporation (OCX) News
Filter OCX News Items
OCX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OCX News Highlights
- For OCX, its 30 day story count is now at 2.
- Over the past 11 days, the trend for OCX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest OCX News From Around the Web
Below are the latest news stories about Oncocyte Corp that investors may wish to consider to help them evaluate OCX as an investment opportunity.
Shareholders in OncoCyte (NASDAQ:OCX) have lost 78%, as stock drops 12% this past weekThe art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But... |
Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceIRVINE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that management will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Presentation Details: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Fireside Chat |
BTIG Thinks OncoCyte’s Stock is Going to RecoverBTIG analyst Mark Massaro reiterated a Buy rating on OncoCyte (OCX – Research Report) yesterday and set a price target of $5.00. The company's shares closed last Wednesday at $1.66, close to its 52-week low of $1.65. According to TipRanks.com, Massaro is a 5-star analyst with an average return of 11.2% and a 51.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as MDxHealth S.A. Sponsored ADR, Ginkgo Bioworks Holdings, and Lucid Diagnostics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for OncoCyte with a $4.05 average price target, which is a 90.1% upside from current levels. |
Needham Thinks OncoCyte’s Stock is Going to RecoverNeedham analyst Michael Matson maintained a Buy rating on OncoCyte (OCX – Research Report) today and set a price target of $5.00. The company's shares closed last Tuesday at $2.19, close to its 52-week low of $1.80. According to TipRanks.com, Matson is a 4-star analyst with an average return of 8.7% and a 53.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings. The word on The Street in general, suggests a Strong Buy analyst consensus rating for OncoCyte with a $4.05 average price target, which is a 105.6% upside from current levels. |
Following agreement with Thermo Fisher, Oncocyte shares plunge 24%Following an after-the-closing bell announcement yesterday of a development and co-marketing agreement with Thermo Fisher Scientific, shares of Oncocyte fell sharply today. |
Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision OncologyCollaboration extends global reach for Thermo Fisher’s rapid next-generation sequencing technology Conference call to be held today at 4:30 pm ET/1:30 pm PT IRVINE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced a development and co-marketing agreement for two d |
What Type Of Shareholders Make Up OncoCyte Corporation's (NASDAQ:OCX) Share Registry?If you want to know who really controls OncoCyte Corporation ( NASDAQ:OCX ), then you'll have to look at the makeup of... |
Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian CancerData show DetermaCNI detects recurrence with higher sensitivity than standard of care biomarkers, high sensitivity with very low false positives DetermaCNI is the first clinical-grade test to monitor for disease progression by detecting instability across the patient’s entire genome in circulating tumor DNA, addressing an unmet need for millions of patients diagnosed with solid and hematological cancers IRVINE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a preci |
Defender Capital LLC. Acquires 613,620 Shares of OncoCyte Co. (NYSEAMERICAN:OCX)Defender Capital LLC. lifted its holdings in OncoCyte Co. (NYSEAMERICAN:OCX) by 45.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,960,820 shares of the biotechnology company’s stock after acquiring an additional 613,620 shares during the period. OncoCyte accounts for approximately […] |
BTIG Research Reiterates Buy Rating for OncoCyte (NYSEAMERICAN:OCX)OncoCyte (NYSEAMERICAN:OCX)s stock had its buy rating reiterated by analysts at BTIG Research in a report released on Friday, TipRanks reports. They presently have a $5.00 price objective on the biotechnology companys stock. BTIG Researchs price target would indicate a potential upside of 131.48% from the companys previous close. A number of other research firms [] |